Last reviewed · How we verify

FF/GW642444 Inhalation Powder — Competitive Intelligence Brief

FF/GW642444 Inhalation Powder (FF/GW642444 Inhalation Powder) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Long-acting beta-2 agonist / Long-acting muscarinic antagonist (LABA/LAMA combination). Area: Respiratory / Pulmonology.

phase 3 Long-acting beta-2 agonist / Long-acting muscarinic antagonist (LABA/LAMA combination) Beta-2 adrenergic receptor; M3 muscarinic receptor Respiratory / Pulmonology Small molecule Live · refreshed every 30 min

Target snapshot

FF/GW642444 Inhalation Powder (FF/GW642444 Inhalation Powder) — GlaxoSmithKline. FF/GW642444 is a dual bronchodilator combining a long-acting beta-2 agonist (formoterol fumarate) and a long-acting muscarinic antagonist (GW642444) to relax airway smooth muscle and improve airflow.

Comparator set (5 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
FF/GW642444 Inhalation Powder TARGET FF/GW642444 Inhalation Powder GlaxoSmithKline phase 3 Long-acting beta-2 agonist / Long-acting muscarinic antagonist (LABA/LAMA combination) Beta-2 adrenergic receptor; M3 muscarinic receptor
Olodaterol-Tiotropium Olodaterol-Tiotropium Fraunhofer-Institute of Toxicology and Experimental Medicine marketed Long-acting beta-2 agonist / Long-acting muscarinic antagonist (LABA/LAMA combination) Beta-2 adrenergic receptor; M3 muscarinic receptor
Vilanterol and Umeclidinium Bromide Vilanterol and Umeclidinium Bromide Samsung Medical Center marketed Long-acting beta-2 agonist / Long-acting muscarinic antagonist combination (LABA/LAMA) Beta-2 adrenergic receptor; M3 muscarinic receptor
indacaterol/glycopyrronium 110/50 Breezhaler® indacaterol/glycopyrronium 110/50 Breezhaler® Wouter H. van Geffen marketed Long-acting beta-2 agonist / Long-acting muscarinic antagonist (LABA/LAMA combination) Beta-2 adrenergic receptor; Muscarinic M3 acetylcholine receptor
Indacaterol/glycopyrronium Indacaterol/glycopyrronium Orion Corporation, Orion Pharma marketed Long-acting beta-2 agonist / Long-acting muscarinic antagonist (LABA/LAMA combination) Beta-2 adrenergic receptor; M3 muscarinic acetylcholine receptor
Anoro® Ellipta® Anoro® Ellipta® AstraZeneca marketed Long-acting beta-2 agonist / Long-acting muscarinic antagonist (LABA/LAMA combination) Beta-2 adrenergic receptor and M3 muscarinic acetylcholine receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Long-acting beta-2 agonist / Long-acting muscarinic antagonist (LABA/LAMA combination) class)

  1. AstraZeneca · 1 drug in this class
  2. Fraunhofer-Institute of Toxicology and Experimental Medicine · 1 drug in this class
  3. GlaxoSmithKline · 1 drug in this class
  4. Orion Corporation, Orion Pharma · 1 drug in this class
  5. Wouter H. van Geffen · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). FF/GW642444 Inhalation Powder — Competitive Intelligence Brief. https://druglandscape.com/ci/ff-gw642444-inhalation-powder. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: